Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy

Chinese Journal of Lung Cancer

Volumn 13, Issue 4, 2010, Pages 337-341

  Wang, Jinghui ^a   Zhang, Quan ^a   Zhang, Hui ^a   Wang, Qunhui ^a   Yang, Xinjie ^a   Gu, Yanfei ^a   Zhang, Shucai ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; ERCC1; Lung neoplasms; Polymorphism

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 77951574462     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.04.13     Document Type: Article

References (14)

1. Rosell R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer, 2002, 38(3): 217-227. (Pubitemid 35341796)
2. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fuorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res, 2005, 11(17): 6212-6217. (Pubitemid 41262950)
3. Park DJ, Zhang W, Stoehlmaeher, et al. ERCCI gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol, 2003, 1(3): 162-166.
4. Yuan P, Miao XP, Zhang XM, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Chin J Cancer, 2005, 24(12): 1510-1513. [2005, 24(12): 1510-1513.] (Pubitemid 40561427)
5. Liu YF, Guan XX, Chen LB, et al. Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer. Chin J Cancer Prev Treat, 2008, 15(17): 1285-1288.
6. Gao CM, Shi MQ, Wu JZ, et al. Polymorphisms in ERCC1, XRCC1 genes and sensitivity to gemcitabine/cisplatin chemotherapy in non-small cell lung cancer. Chin J Cancer Prev Treat, 2009, 16(1): 27-30.
7. Tabaldi C, Tibaldi C, Giovannetti E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small cell lung cancer patients. Clin Cancer Res, 2008, 14(6): 1797-1803.
8. De las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol, 2006, 17(4): 668-675.
9. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10(15): 4939-4943. (Pubitemid 39099767)
10. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 2007, 56(2): 281-288. (Pubitemid 46590484)
11. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 2004, 44(3): 311-316. (Pubitemid 38609439)
12. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol, 2004, 15(8): 1194-1203. (Pubitemid 39199306)
13. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer, 2009, 10(2): 118-123.
14. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol, 2009, 27(21): 3540-3546.